Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic Sclerosis
光学相干弹性成像和断层扫描相结合用于评估系统性硬化症的皮肤受累情况
基本信息
- 批准号:10818828
- 负责人:
- 金额:$ 38.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AreaAssessment toolAutoimmune DiseasesBindingClinicalClinical ResearchClinical TrialsClinical Trials DesignCutaneous sclerosisDataDermalDermisDevelopmentDevicesDiseaseDisease ProgressionDistressElasticityFDA approvedFatty acid glycerol estersFibrosisFingersForearmFunctional ImagingFundingGoalsHistologicHumanImageInterobserver VariabilityLongitudinal cohortMeasurementMeasuresMethodsMonitorMorbidity - disease rateNoiseOptical Coherence TomographyOpticsOrganPalpationPathologyPatientsPerformancePharmaceutical PreparationsPhasePrincipal InvestigatorResolutionRheumatismSclerodermaSignal TransductionSkinSourceStagingStandardizationStructureSystemSystemic SclerodermaTechnologyTexasThickTimeTissuesTrainingUniversitiesVisualizationclinical careclinical developmentclinical practicecohortdensityeffective therapyelastographyexperienceimprovedindium-bleomycinmortalitymouse modelnew technologynoveloptical imagingskillsskin fibrosisstructural imagingsubcutaneoustomographytooltranslational studytreatment responsetreatment strategyultrasound
项目摘要
Abstract
Systemic sclerosis (SSc-scleroderma) is an autoimmune disease leading to widespread fibrosis in skin and
internal organs. Skin involvement is a prominent source of distress and morbidity in this disease. The modified
Rodnan skin score (mRSS) as the current gold standard for assessment of skin thickening has limited accuracy,
high inter-observer variability, requires extensive training which have cumulatively contributed to the fact there
are currently no FDA approved medications for skin involvement in SSc. Therefore, an objective and
accurate tool for assessment of skin fibrosis can be paradigm shifting for clinical trial design and patient
management in SSc by improving our ability to track treatment response and disease progression. Our
preliminary data indicate that the imaging by optical coherence tomography (OCT) and elasticity measurement
by optical coherence elastography (OCE) can provide a safe, rapid, and accurate assessment of SSc skin
fibrosis. Specifically, OCT/OCE is the first objective dermal assessment method showing criterion validity
and outperforming mRSS for correlation with the histological dermal thickness in the forearm area. As the OCE
primarily assesses tissue stiffness, its performance is weaker in some other body areas such as fingers, where
the skin can be tethered to the underlying tissue. On the other hand, an improved high-resolution OCT technology
with accompanying optical density measurement that can image deeper layers of dermis would provide an
additional objective assessment of dermal fibrosis. This is especially relevant in SSc as fibrosis primarily occurs
in deeper layers of dermis (reticular dermis). Our hypothesis is that an improved OCT based structural imaging
that can capture the deeper dermal layers in combination with the OCE based stiffness assessment will improve
our ability to accurately measure dermal fibrosis in SSc. The primary goal of this project to develop and validate
a deep OCT/OCT based tool for assessment of SSc skin thickness. To accomplish this goal, the following
Specific Aims will be pursued during the R61 phase: Aim 1: To enhance signal-to-noise ratio (up to 120 dB) and
imaging depth (up to 2 mm) of the currently available OCE/OCT system for more accurate assessment of SSc
skin. Aim 2: To determine the accuracy of combined OCE and deep dermal OCT imaging for assessment of skin
fibrosis and for monitoring response to treatment in bleomycin induced dermal fibrosis mouse model. Aim 3: To
characterize the accuracy and reliability of a combination of deep OCT/OCE for assessing skin fibrosis in SSc
patients. Building on the above studies, we will characterize the longitudinal changes in the OCE/OCT
assessment of skin fibrosis and determine its sensitivity to change in SSc patients during the R33 phase. This
project can lead to development of a safe and quantitative tool for objective assessment of dermal fibrosis which
can be paradigm shifting by facilitating approval of novel treatments for SSc skin involvement. Moreover,
it can aid clinicians to accurately track disease progression and response to treatment and ultimately lead to
improved monitoring and treatment strategies in this potentially devastating disease.
摘要
系统性硬化症(Ssc-硬皮病)是一种自身免疫性疾病,导致皮肤广泛纤维化,
内脏皮肤受累是这种疾病的痛苦和发病率的主要来源。修改后的
Rodnan皮肤评分(mRSS)作为目前评估皮肤增厚的金标准具有有限的准确性,
观察员之间的高度可变性,需要广泛的培训,这累积起来有助于实现以下事实
目前没有FDA批准的用于SSc皮肤受累的药物。因此,客观和
评估皮肤纤维化的准确工具可以改变临床试验设计和患者
通过提高我们跟踪治疗反应和疾病进展的能力来管理SSc。我们
初步数据表明,光学相干断层扫描(OCT)成像和弹性测量
通过光学相干弹性成像(OCE)可以提供安全,快速和准确的评估SSc皮肤
纤维化具体而言,OCT/OCE是第一个显示标准有效性的客观皮肤评估方法
并且在与前臂区域的组织学真皮厚度的相关性方面优于mRSS。作为OCE
主要评估组织硬度,但在其他一些身体区域(如手指)的性能较弱,
皮肤可以被束缚到下面的组织上。另一方面,改进的高分辨率OCT技术
伴随着可以对真皮深层成像的光密度测量,
皮肤纤维化的额外客观评估。这在SSc中尤其相关,因为纤维化主要发生在
真皮深层(网状真皮)。我们的假设是,一种改进的OCT结构成像
结合基于OCE的硬度评估,可以捕获更深的真皮层,
我们准确测量SSc皮肤纤维化的能力。本项目的主要目标是开发和验证
用于评估SSc皮肤厚度的深度OCT/OCT工具。为了实现这一目标,
在R61阶段将追求具体目标:目标1:提高信噪比(高达120 dB),
目前可用的OCE/OCT系统的成像深度(最大2 mm),可更准确地评估SSc
皮肤目的2:确定OCE和深层皮肤OCT联合成像评估皮肤的准确性
用于在博来霉素诱导的皮肤纤维化小鼠模型中监测对治疗的反应。目标3:
表征深部OCT/OCE组合用于评估SSc皮肤纤维化的准确性和可靠性
患者基于上述研究,我们将描述OCE/OCT的纵向变化
评估皮肤纤维化并确定其对R33期SSc患者变化的敏感性。这
该项目可以导致开发一种用于客观评估皮肤纤维化的安全和定量工具,
可以通过促进SSc皮肤受累的新治疗方法的批准来改变范式。此外,委员会认为,
它可以帮助临床医生准确地跟踪疾病进展和对治疗的反应,
改善对这一潜在破坏性疾病的监测和治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shervin Assassi其他文献
Shervin Assassi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shervin Assassi', 18)}}的其他基金
Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic Sclerosis
干扰素调节因子 7 将干扰素通路激活与系统性硬化症中过度的纤维化反应联系起来
- 批准号:
10682192 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic Sclerosis
光学相干弹性成像和断层扫描相结合用于评估系统性硬化症的皮肤受累情况
- 批准号:
10083443 - 财政年份:2020
- 资助金额:
$ 38.85万 - 项目类别:
Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic Sclerosis
光学相干弹性成像和断层扫描相结合用于评估系统性硬化症的皮肤受累情况
- 批准号:
10247808 - 财政年份:2020
- 资助金额:
$ 38.85万 - 项目类别:
CFlm25 mediated alternative polyadenylation regulates fibrosis in systemic sclerosis
CFlm25介导的选择性多聚腺苷酸化调节系统性硬化症中的纤维化
- 批准号:
10395959 - 财政年份:2019
- 资助金额:
$ 38.85万 - 项目类别:
CFlm25 mediated alternative polyadenylation regulates fibrosis in systemic sclerosis
CFlm25介导的选择性多聚腺苷酸化调节系统性硬化症中的纤维化
- 批准号:
10616484 - 财政年份:2019
- 资助金额:
$ 38.85万 - 项目类别:
Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis
系统性硬化症肺纤维化进展的分子标志物
- 批准号:
8508857 - 财政年份:2011
- 资助金额:
$ 38.85万 - 项目类别:
Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis
系统性硬化症肺纤维化进展的分子标志物
- 批准号:
8165452 - 财政年份:2011
- 资助金额:
$ 38.85万 - 项目类别:
Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis
系统性硬化症肺纤维化进展的分子标志物
- 批准号:
8722440 - 财政年份:2011
- 资助金额:
$ 38.85万 - 项目类别:
Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis
系统性硬化症肺纤维化进展的分子标志物
- 批准号:
8318622 - 财政年份:2011
- 资助金额:
$ 38.85万 - 项目类别:
Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis
系统性硬化症肺纤维化进展的分子标志物
- 批准号:
8786271 - 财政年份:2011
- 资助金额:
$ 38.85万 - 项目类别:
相似海外基金
The potential of using student-conducted ethnographic research as a formative assessment tool in CLIL and EMI courses
在 CLIL 和 EMI 课程中使用学生进行的民族志研究作为形成性评估工具的潜力
- 批准号:
24K04145 - 财政年份:2024
- 资助金额:
$ 38.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing a new risk and needs assessment tool for young people who have displayed harmful sexual behaviour
为表现出有害性行为的年轻人开发新的风险和需求评估工具
- 批准号:
2886506 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Studentship
I-Corps: Remote monitoring and assessment tool for spinal care patients
I-Corps:脊柱护理患者的远程监测和评估工具
- 批准号:
2321802 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Standard Grant
SBIR Phase I: PenEEG: An Objective Assessment Tool for Concussion and Recovery Management
SBIR 第一阶段:PenEEG:脑震荡和恢复管理的客观评估工具
- 批准号:
2304353 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Standard Grant
Development of the Dementia-Friendly Environmental Assessment Tool for Japanese care and nursing homes
为日本护理院和疗养院开发痴呆症友好型环境评估工具
- 批准号:
22KJ0474 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Implementation of an impact assessment tool to optimize responsible stewardship of genomic data in the cloud
实施影响评估工具以优化云中基因组数据的负责任管理
- 批准号:
10721762 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
I-Corps: Sensor-based frailty assessment tool using a smart watch
I-Corps:使用智能手表的基于传感器的虚弱评估工具
- 批准号:
2311611 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Standard Grant
DEVELOPMENT OF DIABETES HEALTH LITERACY ASSESSMENT TOOL TO SUPPORT HEALTHCARE PROVIDERS DURING VIRTUAL VISIT
开发糖尿病健康素养评估工具,在虚拟访问期间为医疗保健提供者提供支持
- 批准号:
495439 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Development of a diagnostic assessment tool and training app for dyscaliculia to apply in medical treatment and education.
开发计算障碍诊断评估工具和培训应用程序,以应用于医疗和教育。
- 批准号:
23K02570 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Injury prevention for rugby-related concussion: development of a comprehensive tackle assessment tool
橄榄球相关脑震荡的伤害预防:开发综合铲球评估工具
- 批准号:
23K16737 - 财政年份:2023
- 资助金额:
$ 38.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




